![[APHA]](/images/logo_apha.svg){kind=logo}
A world-first trial at Sunshine Coast University Private Hospital aims to give new hope to people with difficult-to-treat cancers.
The Phase 1 human clinical trial is testing the safety and effectiveness of a new investigational treatment for patients with advanced solid tumours.
The early-stage research is focused on safety, tolerability, and identifying the most appropriate dose of a novel therapy called ADCX-020.
"To be at the forefront of a world-first trial like this, offering potential new hope for people with difficult-to-treat cancers, aligns with our commitment to delivering exceptional patient care and advancing medical innovation," said the Principal Investigator Dr Michelle Morris, a medical oncologist at Sunshine Coast University Private Hospital.
ADCX-020 treatment combines a chemotherapy drug with a lab-made protein designed to bind to the cancer cell and harness the patient's own immune system to fight cancer.
This targeted therapy, classified as an antibody conjugate, minimises the damage to normal tissue by delivering the chemotherapy directly to the tumour.
Led by experienced clinicians and researchers, the first-in-human trial reflects hospital operator Ramsay Health Care's commitment to safe, reliable care, delivered with strong clinical oversight and a clear focus on patient wellbeing.
Patients with various advanced solid tumours are eligible to participate in this clinical trial.
"Phase 1 trials play a critical role in ensuring that any future treatment is developed on a strong safety foundation," Dr Morris said.
"Aims of the study include identifying any side-effects that may limit dosing and determining the safest dose to guide future Phase 2 trials."
Read more: Oral therapy on trial for incurable arthritis
Read more: Expansion boosts Sunshine Coast services
Next News And Innovation:
9/6/2026 New hospital to meet Victoria's rising mental health needs
Previous News And Innovation:
5/6/2026 'Important upgrade' for treating heart disorder